Polylactic Co Glycolic Acid Plga Nanoparticles For Drug Delivery

Poly(lactic-co-glycolic acid) (PLGA) Nanoparticles for Drug Delivery is a comprehensive guide to PLGA nanoparticles for targeting various diseases, covering principles, formation, characterization, applications, regulations and the latest advances. Sections introduce the fundamental aspects of PLGA nanoparticles for drug delivery, including properties, preparation methods, characterization, drug loading methods, and drug release mechanisms, along with a focus on applications. Application of PLGA nanoparticles for the treatment of cancer, inflammatory, cerebral, cardiovascular, and infectious diseases, as well as in regenerative medicine, photodynamic and photothermal therapy, and gene therapy, are all explained in detail. The final chapters explore recent advances and regulatory aspects. This book is a valuable resource for researchers and advanced students across nanomedicine, polymer science, bio-based materials, chemistry, biomedicine, biotechnology, and materials engineering, as well as for industrial scientists and R&D professionals with an interest in nanoparticles for drug delivery, pharmaceutical formulations and regulations, and development of innovative biodegradable materials. - Presents the fundamentals of PLGA nanoparticles, including properties, preparation, characterization, and biofate and cellular interactions - Provides in-depth coverage of a broad range of specific applications of PLGA nanoparticles across disease treatment, regenerative medicine and therapeutic areas - Offers a methodical approach to PLGA nanoparticles in drug delivery that is supported by data tables, illustrative figures and flowcharts

Poly(lactic-co-glycolic acid) (PLGA) is one of the most successful polymers used for producing therapeutic devices, such as drug carriers (DC). PLGA is one of the few polymers that the Food and Drug Administration (FDA) has approved for human administration due to its biocompatibility and biodegradability. In recent years, DC produced with PLGA has gained enormous attention for its versatility in transporting different type of drugs, e.g., hydrophilic or hydrophobic small molecules, or macromolecules with a controlled drug release without modifying the physiochemical properties of the drugs. These drug delivery systems have the possibility/potential to modify their surface properties with functional groups, peptides, or other coatings to improve the interactions with biological materials. Furthermore, they present the possibility to be conjugated with specific target molecules to reach specific tissues or cells. They are also used for different therapeutic applications, such as in vaccinations, cancer treatment, neurological disorder treatment, and as anti-inflammatory agents. This book aims to focus on the recent progress of PLGA as a drug carrier and their new pharmaceutical applications.

Traumatic brain injury (TBI) presents a serious challenge for modern medicine due to the poor regenerative capabilities of the brain, complex pathophysiology, and lack of effective treatment for TBI to date. The overall goal of this research is to develop as nanoparticle capable of sustained drug release for the delivery and treatment of TBI so that therapeutic drug can be delivered after the Blood Brain Barrier (BBB) closes 24 hours after injury. Poly(lactic-co-glycolic acid) (PLGA) nanoparticles have shown some experimental success; as of yet, none have yielded improved results of clinical efficacy. Polyethylene Glycol (PEG) has been shown to act as a stealth molecule that can increase the circulation time of particles. N-acetylcysteine has shown neuroprotective and anti-inflammatory potential. This paper presents the development of PEGylated PLGA NPs synthesized using double and single emulsion for potential therapeutic delivery to TBI. Dynamic light scattering (DLS) show PEG-PLGA NPs to have an average diameter of 200 nm. Loading capacity was obtained at 2%, and drug encapsulation efficiency was obtained at 55%. A biphasic drug release pattern was noted in situ and drug release was assessed in vitro over 72 h using FRET nanoparticles, almost complete release of drug was seen during this time period. Finally, in vivo administration of PEG-PLGA NPs demonstrated that PEGylated NPS were able to show reduced accumulation in filtration organs such as the liver and kidneys compared to bare PLGA particles. This evidence supports the potential of PEG-PLGA NPs as a promising carrier to develop TBI therapeutics.

This volume presents the proceedings of the 7th Asian-Pacific Conference on Medical and Biological Engineering (APCMBE 2008). Themed "Biomedical Engineering – Promoting Sustainable Development of Modern Medicine" the proceedings address a broad spectrum of topics from Bioengineering and Biomedicine, like Biomaterials, Artificial Organs, Tissue Engineering, Nanobiotechnology and Nanomedicine, Biomedical Imaging, Bio MEMS, Biosignal Processing, Digital Medicine, BME Education. It helps medical and biological engineering professionals to interact and exchange their ideas and experiences.

Poly(lactic-co-glycolic acid) (PLGA) is one of the most successful polymers used for producing therapeutic devices, such as drug carriers (DC). PLGA is one of the few polymers that the Food and Drug Administration (FDA) has approved for human administration due to its biocompatibility and biodegradability. In recent years, DC produced with PLGA has gained enormous attention for its versatility in transporting different type of drugs, e.g., hydrophilic or hydrophobic small molecules, or macromolecules with a controlled drug release without modifying the physiochemical properties of the drugs. These drug delivery systems have the possibility/potential to modify their surface properties with functional groups, peptides, or other coatings to improve the interactions with biological materials. Furthermore, they present the possibility to be conjugated with specific target molecules to reach specific tissues or cells. They are also used for different therapeutic applications, such as in vaccinations, cancer treatment, neurological disorder treatment, and as anti-inflammatory agents. This book aims to focus on the recent progress of PLGA as a drug carrier and their new pharmaceutical applications.

During the recent years, intensive efforts have been devoted to develop novel biodegradable polymeric particulate carriers such as micro- and nanoparticles. These polymeric carriers are capable of offering either localized or targeted drug delivery to specific sites. Most water-soluble drugs suffer from being denatured or cleared from the body before reaching the site of action. In another instance, the frequently administration for some anticancer drugs are not a favourable practice. Toxicity side effect is also often associated with anticancer drug due to uncontrolled drug delivery when it reaches plasma level. Linamarin is a water soluble cyanogenic glucoside compound found abundantly in a variety of plants. Previous research carried out at the University's laboratory showed that linamarin purified from cassava plant has a promising anticancer activity. Meanwhile, clinical administration of free linamarin has been proven to useful to inhibit cancer, but the healthy cells are found to have suffered from cyanide toxicity side effect at the same time. Hence, the selection of an appropriate drug delivery system is a vital step in determining its success as an anticancer drug. It is the main objective of this research to develop poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles (NPs) loaded with linamarin as a novel delivery system for anticancer. Design-Expert Software (Version 6.0.4) was used to design the preparation of linamarin-loaded PLGA nanoparticles. The nanoencapsulation method selected was double emulsion-solvent evaporation technique. The NPs produced were spherical capsules with hollow interior structure, as judged by the scanning and transmission electron microscope micrographs, respectively. Some aggregates were observed in the NPs batches that used surfactant at low concentrations. Similarly, in the batches that utilized higher surfactant concentrations (> 50 mg/ml), some surface residuals which were difficult to be removed were obtained. The zeta potentials of all the formulated nanoparticles showed negative potentials with high absolute values (> 22 mV), indicating their stabilities in dispersion. In addition, the differential scanning calorimeter thermographs revealed that the formulated NPs are amorphous. The cytotoxicity indicated a promising anticancer activity, with the values of IC50 47 and 100μg/ml for free and encapsulated linamarin, respectively. Generally, the results in the yield, drug encapsulation efficiency, and particle size of the NPs designed using the Design-Expert method were ranged as 28 - 94%, 20 - 62%, and 160 - 1500 nm, respectively. The final optimal values of the process parameters were determined at 50 mg/ml, 9.83-10 mg/ml, and 22800-23000 rpm for PVA concentration, PLGA concentration and homogenization speed, respectively. The optimized batches yielded about 95% with 61% drug encapsulation efficiency and particle size

Many key aspects of life are based on naturally occurring polymers, such as polysaccharides, proteins and DNA. Unsurprisingly, their molecular functionalities, macromolecular structures and material properties are providing inspiration for designing new polymeric materials with specific functions, for example, responsive, adaptive and self-healing materials. Bio-inspired Polymers covers all aspects of the subject, ranging from the synthesis of novel polymers, to structure-property relationships, materials with advanced properties and applications of bio-inspired polymers in such diverse fields as drug delivery, tissue engineering, optical materials and lightweight structural materials. Written and edited by leading experts on the topic, the book provides a comprehensive review and essential graduate level text on bio-inspired polymers for biochemists, materials scientists and chemists working in both industry and academia.